Dmitrij Hristodorov
InvestorGeneral Partner at Forbion · Board director at Memento Medicines
Munich, Germany
Writes $100K – $5M checks · typically $1.5M
Find your path to Dmitrij
237 people in our graph share verified history with Dmitrij — schools, employers, funds. One of them is your warm intro.
Vincent RoseunlockedDmitrij: together at Bayer Pharmaceuticals (2017)
×8Dmitrij: together at Bayer Pharmaceuticals
Dmitrij: together at Kynexis
Dmitrij: together at Progentos Therapeutics
About
Dmitrij Hristodorov is a General Partner at Forbion, where his portfolio spans multiple stages, treatment modalities, and disease areas. He previously held R&D Ophthalmology and Business Development roles at Bayer Pharma. He earned a PhD from the University of Aachen (RWTH) in 2013 for immunology work conducted at the Fraunhofer Institute.
Invests in
Biotech
Board director at Memento Medicines
Intro paths
→
In turn, Dmitrij can intro founders to Memento Medicines's investors below.
Experience
- ForbionGeneral Partnercurrent2024 — presentMünchen, Bayern, Deutschland
- ForbionPartner2021 — 2024München, Bayern, Deutschland
- ForbionPrincipal2021München, Bayern, Deutschland
- ForbionSenior Associate2020München, Bayern, Deutschland
- Memento MedicinesBoard Membercurrent2026 — present
- Mosanna TherapeuticsBoard Membercurrent2025 — present
- Beacon TherapeuticsBoard Membercurrent2024 — present
- Progentos TherapeuticsBoard Membercurrent2024 — present
- KynexisBoard Membercurrent2022 — present
- AAVantgarde BioBoard Membercurrent2023 — presentItaly
- Seamless TherapeuticsBoard Membercurrent2022 — present
- Complement TherapeuticsBoard Membercurrent2022 — present
- RyCarma TherapeuticsBoard Membercurrent2021 — present
- Rampart BioscienceBoard Member2023 — 2025
- OxularBoard Member2021 — 2024Oxford
- VectorYBoard Observer2020 — 2023Amsterdam
- Gyroscope TherapeuticsBoard Observer2021 — 2022Stevenage
- Bayer PharmaceuticalsSenior Director, Global Business Development & Licensing2018 — 2020Berlin Area, Germany
- Bayer PharmaceuticalsDirector, Early Licensing, Global Business Development2016 — 2018Berlin Metropolitan Area
- Bayer PharmaceuticalsProject Leader/Alliance Manager2015Baltimore, Maryland Area
- Bayer PharmaceuticalsHead of Laboratory (Ophthalmology)2013 — 2015Wuppertal
- Fraunhofer IMEResearch Scientist (PostDoc)2013Kreisfreie Stadt Aachen Area, Germany
- Fraunhofer IMEResearch Scientist (PhD student)2011 — 2013Aachen
- antibodies-online.comData Management2012 — 2013Aachen
- Bayer HealthCareMaster Student2010 — 2011Wuppertal Area, Germany
- Fraunhofer CMBBachelor Student2009Newark, Delaware, USA
Skills & more
Life Sciences27Business Development12Ophthalmology12Immunology19Biotechnology10Licensing2Cancer Research13Inflammation8Pharmaceutical Industry2Drug Development3
Languages English · German · Russian
From Dmitrij's professional profile.
Deals · 1
Memento MedicinesBoard seat
via Forbion · filed Jun 2026 · $93M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
AAVantgardeBeaconComplementGyroscope TherapeuticsKynexisMosannaOxularRampart BioRyCarmaSeamlessVectorY Therapeutics
Sources: the firm's website · SEC Form D filings.
Colleagues at Forbion
Alexander Hoffmann
General Partner at Forbion
Alice Vickers
Advisor at Forbion
Antoine Boulanger Piette
Principal at Forbion
Audrey Cacaly
Principal at Forbion
Carlo Incerti
Operating Partner at Forbion
Dirk Kersten
Managing Partner at Forbion
Geert-Jan Mulder
Managing Partner at Forbion
Holger Reithinger
General Partner at Forbion
Network6
Alice Vickers
Advisor at Forbion
Antoine Boulanger Piette
Principal at Forbion
Audrey Cacaly
Principal at Forbion
Dan Janney
Managing Director at Alta Partners
Dirk Kersten
Managing Partner at Forbion
Holger Reithinger
General Partner at Forbion
Investors connected to Dmitrij in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Dmitrij Hristodorov?
- Dmitrij Hristodorov is a General Partner at Forbion, where his portfolio spans multiple stages, treatment modalities, and disease areas. He previously held R&D Ophthalmology and Business Development roles at Bayer Pharma. He earned a PhD from the University of Aachen (RWTH) in 2013 for immunology work conducted at the Fraunhofer Institute.
- Where does Dmitrij Hristodorov work?
- Dmitrij Hristodorov is General Partner at Forbion and Board director at Memento Medicines.
- What does Dmitrij Hristodorov invest in?
- Dmitrij Hristodorov invests in Biotech.
- What check size does Dmitrij Hristodorov write?
- Dmitrij Hristodorov typically writes checks of $100K – $5M.
- What boards does Dmitrij Hristodorov sit on?
- Dmitrij Hristodorov holds tracked board seats at AAVantgarde, Beacon, Complement, Gyroscope Therapeutics, Kynexis, Memento Medicines, Mosanna, Oxular, Rampart Bio, RyCarma.
- Where did Dmitrij Hristodorov go to school?
- Dmitrij Hristodorov studied at RWTH Aachen University (Dr. rer. nat. (PhD), Biotechnology; Immunology); RWTH Aachen University (Master of Science (MS), Biotechnology); RWTH Aachen University (Bachelor of Science (BS), Biotechnology).
Same school
Also attended RWTH Aachen University111
Paula SchultheissSenior Associate at AN Venture PartnersStefan TirteyManaging Partner at CommerzVenturesDr. Nils EiteneyerPartner at CapnamicJason GrüningerInvestment Manager at CapnamicAbdulla ElyasAdvisor at RAED VenturesFrederike WolffInvestment Team at Redstone
.avif)
+ 105 more
Shared employers
Also worked at RyCarma Therapeutics1
Also worked at Oxular3
Also worked at VectorY8
Carlo IncertiOperating Partner at ForbionAlexander VosVenture Partner at BioGeneration VenturesElena RitsouVenture Partner at BioGeneration VenturesMarco BoorsmaGeneral Partner at ForbionWouter JoustraGeneral Partner at ForbionRianne EllenbroekPrincipal at BioGeneration Ventures
+ 2 more
